Frankfurt - Delayed Quote EUR

AngioDynamics, Inc. (UG2.F)

Compare
8.45
+0.05
+(0.60%)
At close: December 30 at 1:39:22 PM GMT+1
Loading Chart for UG2.F
DELL
  • Previous Close 8.40
  • Open 8.45
  • Bid 8.45 x 25800
  • Ask 9.50 x 24800
  • Day's Range 8.45 - 8.45
  • 52 Week Range 4.76 - 8.95
  • Volume 100
  • Avg. Volume 42
  • Market Cap (intraday) 357.697M
  • Beta (5Y Monthly) 0.67
  • PE Ratio (TTM) --
  • EPS (TTM) -5.80
  • Earnings Date Jan 8, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

www.angiodynamics.com

748

Full Time Employees

May 31

Fiscal Year Ends

Recent News: UG2.F

View More

Performance Overview: UG2.F

Trailing total returns as of 12/31/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

UG2.F
19.01%
S&P 500
23.31%

1-Year Return

UG2.F
19.01%
S&P 500
23.31%

3-Year Return

UG2.F
65.65%
S&P 500
23.08%

5-Year Return

UG2.F
39.64%
S&P 500
82.59%

Compare To: UG2.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: UG2.F

View More

Valuation Measures

As of 12/30/2024
  • Market Cap

    352.63M

  • Enterprise Value

    304.49M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.22

  • Price/Book (mrq)

    1.82

  • Enterprise Value/Revenue

    1.08

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -83.02%

  • Return on Assets (ttm)

    -6.12%

  • Return on Equity (ttm)

    -77.85%

  • Revenue (ttm)

    292.73M

  • Net Income Avi to Common (ttm)

    -243.03M

  • Diluted EPS (ttm)

    -5.80

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    55.01M

  • Total Debt/Equity (mrq)

    2.76%

  • Levered Free Cash Flow (ttm)

    24.19M

Research Analysis: UG2.F

View More